NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Minerva Neurosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.32−0.03 (-1.28%)
Close on Oct 19, 2026
- Market cap
- $183.52M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.17 (−6.83%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $183.52M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$394.35M
- EPS, diluted
- -$34.67
- Book value per share
- -$2.70
- Diluted shares
- 79M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$35.14M
Net income
-$394.35M-3611.7% YoY
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months